AI assistant
Aquestive Therapeutics, Inc. — Director's Dealing 2018
Sep 5, 2018
32552_dirs_2018-09-05_b68ccf5a-bf31-4089-b7ce-e90a1c1305a9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aquestive Therapeutics, Inc. (AQST)
CIK: 0001398733
Period of Report: 2018-08-31
Reporting Person: Kendall Keith J (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-08-31 | Common Stock | M | 14572 | — | Acquired | 1014572 | Direct |
| 2018-08-31 | Common Stock | F | 6510 | $18.01 | Disposed | 1008062 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-08-31 | Restricted Stock Unit | $ | M | 14572 | Disposed | Common Stock (14572) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: Includes 396,040 shares of common stock currently issued and outstanding, which are held by Mr. Kendall in constructive trust for his former spouse pursuant to a divorce settlement agreement reached in November 2016 and which will be transferred and come under the control of Mr. Kendall's former spouse in the near future.
F3: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on August 31, 2018, subject in each case to Mr. Kendall's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof.